Yun Song, Eunise Chen, Yi‐Ju Chiang, James C. Yao, Daniel M. Halperin, Deyali Chatterjee, Brian D. Badgwell
{"title":"Classification of Gastric Neuroendocrine Tumors and Associations With Survival","authors":"Yun Song, Eunise Chen, Yi‐Ju Chiang, James C. Yao, Daniel M. Halperin, Deyali Chatterjee, Brian D. Badgwell","doi":"10.1002/jso.27876","DOIUrl":null,"url":null,"abstract":"Background and ObjectivesNot all gastric neuroendocrine tumors (GNETs) may be classified into one of the three described clinicopathologic subtypes. The purpose of this study was to better characterize GNET subtypes and associated outcomes.MethodsPatients treated for GNET at our institution (1995−2021) were identified. Pathologic specimens of tumors that could not be classified as type 1, 2, or 3 were further reviewed. GNETs were categorized as proton pump inhibitor (PPI)‐associated based on changes in the background gastric mucosa consistent with PPI use. Distant metastasis at presentation (DM) and disease‐specific survival (DSS) were evaluated.ResultsAmong 246 patients, there were 164 (67%) type 1, 5 (2%) type 2, 52 (21%) type 3, and 18 (7%) PPI‐associated GNETs. Seven (3%) tumors remained unclassified. DM was more frequent with type 3 GNETs (38%) than type 1 (1%), type 2 (20%), or PPI‐associated tumors (11%, <jats:italic>p</jats:italic> < 0.001). Ten‐year DSS rates were 100% for type 1, 53% (95% confidence interval [CI], 38%−75%) for type 3, and 80% (95% CI, 58%−100%) for PPI‐associated tumors (<jats:italic>p</jats:italic> < 0.001). GNET subtype, race, and DM were independently associated with DSS.ConclusionsPPI‐associated tumors may represent a distinct GNET subtype with intermediate outcomes. Other factors should also be considered in overall prognosis.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.27876","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and ObjectivesNot all gastric neuroendocrine tumors (GNETs) may be classified into one of the three described clinicopathologic subtypes. The purpose of this study was to better characterize GNET subtypes and associated outcomes.MethodsPatients treated for GNET at our institution (1995−2021) were identified. Pathologic specimens of tumors that could not be classified as type 1, 2, or 3 were further reviewed. GNETs were categorized as proton pump inhibitor (PPI)‐associated based on changes in the background gastric mucosa consistent with PPI use. Distant metastasis at presentation (DM) and disease‐specific survival (DSS) were evaluated.ResultsAmong 246 patients, there were 164 (67%) type 1, 5 (2%) type 2, 52 (21%) type 3, and 18 (7%) PPI‐associated GNETs. Seven (3%) tumors remained unclassified. DM was more frequent with type 3 GNETs (38%) than type 1 (1%), type 2 (20%), or PPI‐associated tumors (11%, p < 0.001). Ten‐year DSS rates were 100% for type 1, 53% (95% confidence interval [CI], 38%−75%) for type 3, and 80% (95% CI, 58%−100%) for PPI‐associated tumors (p < 0.001). GNET subtype, race, and DM were independently associated with DSS.ConclusionsPPI‐associated tumors may represent a distinct GNET subtype with intermediate outcomes. Other factors should also be considered in overall prognosis.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.